3mon
Bloomberg on MSNWuXi AppTec Says Advanced Therapy Unit Hit Despite Revenue Beat(Bloomberg) -- WuXi AppTec Co. posted better-than-expected third-quarter revenue despite concerns over a US bill seeking to ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Rockville’s MaxCyte has made its first acquisition in its more than quarter-century of operation. It’s keeping its eyes out ...
The company’s innovative use of the Varian ProBeam Compact proton therapy system, operational since June 2023, is seen as a key driver of this growth. Despite a loss of $37.4 million ...
Such preliminary revenue results for full year 2024 are ... and cell and gene therapy companies. Forward-Looking Statements This press release contains, and our officers and representatives ...
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
“In 2024 we grew our business with four products in five indications globally, exceeding the updated revenue guidance we ... launch of our first gene therapy, in Sanfilippo syndrome, and to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results